Seizure Drugs: Adult Efficacy Data May Be Extrapolated To Pediatric Patients
US FDA final guidance on partial onset seizure drugs reflects only one major change from an earlier draft version: the lowering of the youngest age for which extrapolation of efficacy is appropriate, from four years to two years.
You may also be interested in...
US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.
239 Days: Oncopeptides' Myeloma Drug Pepaxto Comes Off Market Just Months After Accelerated Approval
Withdrawal announcement marks shortest interval ever from accelerated approval to market removal after OCEAN confirmatory trial showed an adverse overall survival trend and US FDA said a hypothesis-generating subgroup analysis would need to be borne out in another study.
US CDC Panel Supports Moderna, Janssen COVID Vaccine Boosters But Strips Out Preference Language For Homologous Dosing
ACIP pushes back on proposed policy recommendation that the same product used for the primary regimen should be used for the booster, saying risk/benefit and other considerations necessitate more flexibility afforded by 'mix and match' approach.